(Total Views: 316)
Posted On: 12/21/2017 9:25:00 AM
Post# of 30066
Quote:
Updating Price Target to $0.65
We are updating the price target of AMBS following recent developments at the company. The target is based on the potential value from advancing candidates at Elto Pharma and Cutanogen, taking into consideration the liabilities at the AMBS level. We see the AMBS as a high risk, high potential reward company emerging from distressed status.
about 600% higher then where we ended yesterday.... i'll TAKE IT!
(7)
(0)
